Browsed by
Category: Press Releases

NFP’s InsurChoice™ Empowers Organizations to Offer Customized Insurance Coverages Directly to Their Employees or Members

NFP’s InsurChoice™ Empowers Organizations to Offer Customized Insurance Coverages Directly to Their Employees or Members

NEW YORK, September 7, 2021 –, a leading insurance broker and consultant providing corporate benefits, property and casualty (P&C), retirement and individual solutions, today introduced InsurChoice, a digital marketplace that provides businesses, membership organizations and strategic partners the opportunity to offer personal insurance solutions to their employees, members and customers. ...  Read more

Adaptive Phage Therapeutics Awarded Additional $8 Million from U.S. Department of Defense for Clinical Advancement of Phage to Address Unmet Needs in Infectious Diseases

Adaptive Phage Therapeutics Awarded Additional $8 Million from U.S. Department of Defense for Clinical Advancement of Phage to Address Unmet Needs in Infectious Diseases

GAITHERSBURG, MD, September 30, 2021 – Adaptive Phage Therapeutics, Inc. (APT), a clinical-stage biotechnology company dedicated to providing therapies to treat infectious diseases, today announced that the Department of Defense (DoD) has awarded the company an additional $8 million for the continued development of bacteriophage therapies (PhageBankTM) for the treatment of infectious diseases. The new funding brings the total contract awarded to APT to $31.2 million. ...  Read more

Supernus Pharmaceuticals To Acquire Adamas Pharmaceuticals For $450 Million

Supernus Pharmaceuticals To Acquire Adamas Pharmaceuticals For $450 Million

ROCKVILLE, Md. and EMERYVILLE, Calif., Oct. 11, 2021 (GLOBE NEWSWIRE) — Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN) and Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), today announced a definitive agreement for Supernus to acquire Adamas through a tender offer for $8.10 per share in cash (or an aggregate of approximately $400 million), payable at closing plus two non-tradable contingent value rights (CVR) collectively worth up to $1.00 per share in cash (or an aggregate of approximately $50 million), for a total consideration of $9.10 per share in cash (or an aggregate of approximately $450 million). ...  Read more

QIAGEN Receives U.S. Department of Defense Contract to Further Expand Production Capacity for NeuMoDx

QIAGEN Receives U.S. Department of Defense Contract to Further Expand Production Capacity for NeuMoDx

September 30, 2021 04:48 PM Eastern Daylight Time

GERMANTOWN, Md. & HILDEN, Germany–(BUSINESS WIRE)–QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it had won a U.S. government contract to increase the production capacity for consumables used on its NeuMoDx 96 and 288 integrated PCR testing systems, an important step to support laboratory testing as the COVID-19 pandemic continues. ...  Read more

SYNAPS Dx Closes $10 Million Series A Investment

SYNAPS Dx Closes $10 Million Series A Investment

ROCKVILLE, Md.–(BUSINESS WIRE)–SYNAPS Dx (SDx), a privately held company focused on the research, development and commercialization of diagnostics for neurodegenerative disorders and conditions, including Alzheimer’s Disease (AD), announces the close of its Series A $10 million investment, including private equity, individual and family funds, and corporate investors. ...  Read more

Blu Venture Partners Join $9.5 Million Series A for cloudtamer.io

Blu Venture Partners Join $9.5 Million Series A for cloudtamer.io

FULTON, Md.–(BUSINESS WIRE)–cloudtamer.io, the leading automated multi-cloud governance and management solution provider, today announced that it has raised a $9.5 million Series A funding round led by Blue Heron Capital and TDF Ventures, with participation from Blu Venture Investors, Early Light Ventures and Gaingels. This funding will be used to expand its sales and marketing operations as well as its engineering team to fuel company growth and bring enhanced cloud governance and management capabilities to market. ...  Read more

IPS Acquires Linesight and Partners for Strategic Growth

IPS Acquires Linesight and Partners for Strategic Growth

BLUE BELL, PA, USA & DUBLIN, IRELAND, October 18th, 2021 – IPS-Integrated Project Services, LLC, headquartered in Blue Bell, Pennsylvania and a subsidiary of Alleghany Capital Corporation, today announced that it has acquired Linesight, a multinational consulting firm headquartered in Dublin, Ireland. IPS is a large EPCMV (Engineering, Procurement, Construction Management and Validation) company with over 1,700 staff across 22 offices worldwide. ...  Read more

FITCI’s Nanobiofab shapes medical training with AI-powered platform

FITCI’s Nanobiofab shapes medical training with AI-powered platform

Tao Treasures LLC DBA Nanobiofab, a minority woman-owned nanotech startup in the Frederick Innovative Technology Center, Inc. (FITCI), is helping medical mannequins tell doctors where it hurts. The company, which creates revolutionary million-scale nanomaterial used in applications ranging from routine health monitoring to cancer detection, is working with West Virginia University (WVU) to improve clinical simulators. The million-dollar effort, initiated through the Defense Health Agency Small Business Innovation Research (SBIR) program, starts in September at Nanobiofab (Frederick, MD) and the David and Jo Ann Shaw Center for Simulation Training and Education for Patient Safety (STEPS) at WVU in Morgantown, WV. ...  Read more

Zalgen Awarded CEPI Contract to Provide Test Kits for Largest Ever Lassa Fever Study in West Africa

Zalgen Awarded CEPI Contract to Provide Test Kits for Largest Ever Lassa Fever Study in West Africa

Three-year contract leading to advance clinical trials for Lassa Fever vaccines reaffirms Zalgen’s focus on preparedness and its dedication to developing solutions for emerging viral threats

 Oslo, Norway & Germantown, Maryland, August 25, 2021 – Zalgen Labs LLC (Zalgen), a biotechnology and diagnostics company focused on preparedness for high impact, neglected infectious diseases including Lassa Fever (LF), today announced its contract with the Coalition for Epidemic Preparedness Innovations (CEPI) to further advance the development of vaccines against Lassa Fever (LF) in West Africa, a region where the disease is endemic. ...  Read more